Celgene has been having some problems developing new drugs, but its Revlimid is the world’s best selling cancer drug – and the company is preparing to build on this with a filing in the new year.

Celgene has added another new indication for its blood cancer blockbuster Revlimid, with the FDA approving its use alongside Roche’s Rituxan for two additional forms of indolent non-Hodgkin’s ...

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

Lenalidomide (REVLIMID®) CC-5013 (Celgene, NJ, USA) is approved, in both the USA and Europe, in combination with dexamethasone for the treatment of multiple myeloma patients who have received at ...

“The complaint…asserts claims under federal antitrust law alleging that Dr Reddy’s, acting in connection with Celgene Corporation ... of brand and generic Revlimid through their respective ...

Celgene, based in New Jersey, had more than $11.2bn in global sales in the first nine months of 2018, up about 18% on the year before. But the firm is fighting to preserve its patent for Revlimid ...

The company also continues to navigate generic competition for its cancer drug Revlimid, which it acquired as part of its 2019 deal for cancer specialist Celgene. However, the drugmaker's third ...

Graham Burton, M.D., Regulatory Affairs and Pharmacovigilance said that FDA’s approval of REVLIMID (lenalidomide) offered a new oral drug option to multiple myeloma patients. Graham Burton, M.D ...